Xu D - Search Results

1

Integrative analysis of the role of BOLA2B in human pan-cancer.

Liang M, Fei Y, Wang Y, Chen W, Liu Z, Xu D, Shen H, Zhou H, Tang J. Liang M, et al. Among authors: xu d. Front Genet. 2023 Feb 27;14:1077126. doi: 10.3389/fgene.2023.1077126. eCollection 2023. Front Genet. 2023. PMID: 36923798 Free PMC article.

2

Endoplasmic reticulum stress targeted therapy for breast cancer.

Xu D, Liu Z, Liang MX, Fei YJ, Zhang W, Wu Y, Tang JH. Xu D, et al. Cell Commun Signal. 2022 Nov 7;20(1):174. doi: 10.1186/s12964-022-00964-7. Cell Commun Signal. 2022. PMID: 36345017 Free PMC article. Review.

3

Glucose metabolism and lncRNAs in breast cancer: Sworn friend.

Xu JL, Xu Q, Wang YL, Xu D, Xu WX, Zhang HD, Wang DD, Tang JH. Xu JL, et al. Among authors: xu wx, xu q, xu d. Cancer Med. 2023 Feb;12(4):5137-5149. doi: 10.1002/cam4.5265. Epub 2022 Nov 24. Cancer Med. 2023. PMID: 36426411 Free PMC article.

4

Dietary patterns, nutritional status, and mortality risks among the elderly.

Liu Z, Xu D, Xu WX, Fei YJ, Wang DD, Deng F, Tang JH. Liu Z, et al. Among authors: xu wx, xu d. Front Nutr. 2022 Dec 9;9:963060. doi: 10.3389/fnut.2022.963060. eCollection 2022. Front Nutr. 2022. PMID: 36570143 Free PMC article.

5

CBX3 promotes breast cancer progression and high level of CBX3 predicts poor prognosis in patients.

Yang K, Wang YL, Zhu Z, Cao XH, Liang MX, Xu D, Fei YJ, Yang SY, Zhou HL, Tang JH. Yang K, et al. Among authors: xu d. Neoplasma. 2023 Feb;70(1):71-81. doi: 10.4149/neo_2022_220622N656. Epub 2023 Jan 9. Neoplasma. 2023. PMID: 36620876

6

Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma.

Shen HY, Zhang J, Xu D, Xu Z, Liang MX, Chen WQ, Tang JH, Xia WJ. Shen HY, et al. Among authors: xu d, xu z. Medicine (Baltimore). 2023 Apr 14;102(15):e33530. doi: 10.1097/MD.0000000000033530. Medicine (Baltimore). 2023. PMID: 37058053 Free PMC article.

7

Hyperthermia promotes M1 polarization of macrophages via exosome-mediated HSPB8 transfer in triple negative breast cancer.

Xu D, Liu Z, Liang MX, Chen WQ, Fei YJ, Yang SJ, Wu Y, Zhang W, Tang JH. Xu D, et al. Discov Oncol. 2023 May 26;14(1):81. doi: 10.1007/s12672-023-00697-0. Discov Oncol. 2023. PMID: 37233869 Free PMC article.

8

Tumor-derived small extracellular vesicles promote breast cancer progression by upregulating PD-L1 expression in macrophages.

Xu D, Chen WQ, Liang MX, Chen X, Liu Z, Fei YJ, Shao XY, Wu Y, Zhang W, Tang JH. Xu D, et al. Cancer Cell Int. 2023 Jul 14;23(1):137. doi: 10.1186/s12935-023-02980-0. Cancer Cell Int. 2023. PMID: 37452413 Free PMC article.

9

Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients.

Shen HY, Xu JL, Zhu Z, Xu HP, Liang MX, Xu D, Chen WQ, Tang JH, Fang Z, Zhang J. Shen HY, et al. Among authors: xu jl, xu d, xu hp. Neoplasia. 2023 Nov;45:100942. doi: 10.1016/j.neo.2023.100942. Epub 2023 Oct 13. Neoplasia. 2023. PMID: 37839160 Free PMC article.

10

TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2⁺ breast cancer.

Shao X, Yang D, Shan L, Yan X, Xu D, Li L, Sun Y, Yu Q, Zhou H, Ding Y, Tang J. Shao X, et al. Among authors: xu d. Arch Toxicol. 2024 Mar;98(3):865-881. doi: 10.1007/s00204-023-03670-6. Epub 2024 Jan 11. Arch Toxicol. 2024. PMID: 38212449

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16,672 results

Search Page